TsakonasEJosephLEsdaileJM. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus1998; 7: 80–85.
2.
LeveyASStevensLASchmidCH. A new equation to estimate glomerular filtration rate. Ann Intern Med2009; 150: 604–612.
3.
Costedoat-ChalumeauNAmouraZHulotJS. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum2006; 54: 3284–3290.
4.
Costedoat-ChalumeauNGalicierLAumaitreO. Hydroxychloroquine in systemic lupus erythematosus: Results of a French multicentre controlled trial (PLUS Study). Ann Rheum Dis2012; Nov 10.
5.
FurstDE. Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus1996; 5 Suppl 1: S11–5.
6.
BernsteinHN. Ocular safety of hydroxychloroquine sulfate (Plaquenil). South Med J1992; 85: 274–279.
